Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial
Adj AVD at these doses enabled 35% more iPTH reduction in ND-CKD patients with mild to moderate SHPT on long-term ERC treatment but increased mean serum Ca and P by 0.40 and 0.27 mg/dL, respectively, FGF23 by more than 2-fold, and eGFR decline by 4-fold, suggesting that adding AVD to ERC has untoward effects that override the nephrosparing impact of iPTH reductions with ERC treatment alone. Corroboration is warranted with a larger, longer RCT.
Authors
- Edgar V. Lerma (ORCID: https://orcid.org/0000-0002-0976-5478)
- Nilay Patel
- Stuart M. Sprague (ORCID: https://orcid.org/0000-0002-3330-0179)
- Akhtar Ashfaq (ORCID: https://orcid.org/0000-0002-0501-8571)
- Keith C. Norris (ORCID: https://orcid.org/0000-0003-3071-0700)
- P. Martin Petkovich
- John Choe (ORCID: https://orcid.org/0000-0003-1019-3849)
- Charles W. Bishop (ORCID: https://orcid.org/0000-0002-7877-6795)
- Stephen A. Strugnell
Institutions
- NorthShore University HealthSystem (US)
- University of California, Los Angeles (US)
- Queen's University (CA)
- OPKO Health (United States) (US)
- Associates in Neurology (US)
Publication Details
- Journal
- American Journal of Nephrology
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1159/000544086
- Citations
- 1
- Primary Topic
- Vitamin D Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47